癌症基因治疗市场规模、份额及成长分析（按类型、治疗方法、产品、最终用途和地区）－2025-2032 年产业预测

预计 2023 年全球癌症基因治疗市场规模将达到 35 亿美元，从 2024 年的 42.5 亿美元成长到 2032 年的 200.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 21.4%。

全球癌症发生率的上升对癌症基因治疗市场的成长产生了重大影响。主要驱动因素包括对创新癌症治疗的需求不断增加、基因工程技术的进步以及对开发新治疗方法的大量投资。由于正在进行的肿瘤学研究以及对个人化治疗方案以提高存活率的需求，公司正在优先开发新的基因疗法。此外，政府对癌症患者的支持为治疗提供者创造了更多机会。然而，高昂的治疗成本、潜在的副作用以及製造障碍等挑战可能会限制市场的长期发展潜力。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

癌症基因治疗市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• 体外
• 体内

癌症基因治疗市场规模（按治疗方法类型和复合年增长率）（2025-2032）

• 市场概览
• 溶瘤病毒疗法
• 基因导向免疫治疗
• 基因转移

癌症基因治疗市场规模（按产品和复合年增长率） (2025-2032)

• 市场概览
• 病毒载体
  • 腺病毒
  • 慢病毒
  • 逆转录病毒
  • 腺结合病毒
  • 单纯疱疹病毒
  • 痘苗病毒
  • 其他病毒载体
• 非病毒载体
• 其他产品

癌症基因治疗市场规模（按最终用途和复合年增长率） (2025-2032)

• 市场概览
• 生物製药公司
• 研究组织
• 其他最终用途

癌症基因治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（USA）
• Bristol Myers Squibb Company（USA）
• CRISPR Therapeutics（Switzerland）
• Amgen Inc.（USA）
• Merck KGaA（Germany）
• Intellia Therapeutics, Inc.（USA）
• Adaptimmune Therapeutics（UK）
• Autolus Therapeutics（UK）
• Sangamo Therapeutics, Inc.（USA）
• Vertex Pharmaceuticals（USA）
• Abeona Therapeutics Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• AstraZeneca（UK）
• Takeda Pharmaceutical Company Limited（Japan）

结论和建议

Global Cancer Gene Therapy Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 4.25 billion in 2024 to USD 20.05 billion by 2032, growing at a CAGR of 21.4% during the forecast period (2025-2032).

The rising global incidence of cancer is significantly influencing the growth of the cancer gene therapy market. Key drivers include an increasing demand for innovative cancer treatments, advancements in genetic engineering technologies, and substantial investments directed towards the development of novel therapies. Companies are prioritizing the creation of new gene therapies fueled by ongoing research in oncology and the desire for personalized treatment options, which aim to enhance survival rates. Moreover, government support for cancer patients presents additional opportunities for therapy providers. However, challenges such as the high cost of treatments, the potential for adverse effects, and manufacturing hurdles could limit the market's long-term development potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Gene Therapy Market Segments Analysis

Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is significantly propelled by advancements in genetic engineering and genome mapping technologies, which have seen substantial investments in gene research initiatives. These breakthroughs in genetics are increasingly converging with oncology research, leading to the development of innovative cancer gene therapies. This integration not only enhances treatment options but also stimulates market expansion, reflecting the growing importance of personalized medicine in addressing complex cancer challenges. As these technologies evolve, they are set to further accelerate the growth of the cancer gene therapy sector, ultimately striving to improve patient outcomes and revolutionize cancer treatment methodologies.

Restraints in the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market faces significant restraints primarily due to the high costs associated with these advanced treatments. The expenses incurred from sophisticated equipment and thorough research and development processes make gene therapy inaccessible for many cancer patients. These financial barriers hinder the widespread adoption of cancer gene therapy, as not all patients can afford the treatment. Consequently, the high pricing remains a critical factor that limits the potential growth of the market, as cost-effective alternatives are often sought in the pursuit of effective cancer therapies. This economic limitation poses challenges for both patients and healthcare providers in accessing these innovative solutions.

Market Trends of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is witnessing a significant trend toward the growing demand for combination therapies, driven by an increasing number of cancer patients seeking enhanced survival rates and improved treatment outcomes. This shift presents a strategic opportunity for cancer gene therapy providers to innovate and expand their offerings by developing novel combination therapies that synergistically leverage the effects of various treatment modalities, such as targeted therapies, immunotherapies, and traditional chemotherapies. By prioritizing research and collaboration, these providers can not only address the evolving needs of patients but also maximize their market potential and reinforce their competitive edge in the long-term landscape of oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Gene Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Cancer Gene Therapy Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Oncolytic Virotherapy
• Gene-Induced Immunotherapy
• Gene Transfer

Global Cancer Gene Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Viral Vectors
  • Adenoviruses
  • Lentiviruses
  • Retrovirus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Vaccinia Virus
  • Other Viral Vectors
• Non-Viral Vectors
• Other Products

Global Cancer Gene Therapy Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Biopharma Companies
• Research Institutes
• Other End-Users

Global Cancer Gene Therapy Market Size & CAGR (2025-2032)

• North America (Type, Therapy, Product, End Use)
  • US
  • Canada
• Europe (Type, Therapy, Product, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapy, Product, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapy, Product, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapy, Product, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abeona Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations